How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across ...

Initiation of a single, two-part, pivotal Phase 3 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) anticipated by ...

SAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and ...

Jamie Rauscher, LVT, president of NAVTA, outlined 5 essential steps veterinary technicians should follow for an effective ...

Adipo Therapeutics LLC, a late-stage, preclinical biopharmaceutical company developing a potential treatment for obesity and ...

Adipo's treatment has the potential to increase energy expenditure by creating healthier, energy-burning, metabolically beneficial subcutaneous fat." The first study examined the effect of ADPO-002 ...

Amid current economic uncertainties and market volatility, investing in defensive stocks appears as an ideal strategy for ...

KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and ...

Topline results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in patients with MASH and liver fibrosis.

KORU Medical Systems is poised for growth with solid revenue increases and multiple growth drivers. Find out why KRMD stock ...

Celltrion plans to commercialize 22 biosimilars by 2030, expanding its global presence with robust sales growth driven by ...